AI-developed drug Rentosertib shows 3-4 year reversal of biological age in humans
coherence · x · 2026-09-08
Rentosertib, the first drug designed end-to-end with AI by Insilico Medicine and now in Phase 3 trials, has shown what researchers call a reversal—not just a slowdown—of biological aging in humans.
- After 12 weeks of treatment, six independent aging clocks developed by six separate groups all measured participants as biologically 3-4 years younger
- The result is being hailed as a landmark for AI-driven drug discovery and a milestone toward the longer-term goal of fully reversing aging
Caveats: the data come from a single investigational drug's trial, and aging-clock methodology remains debated; clinical significance awaits full Phase 3 results.
Related event: AI-Designed IPF Drug Rentosertib Shows Biological Age Reversal in Trial(18 posts)→
More from Research
- Token Collapse: Study Finds Graph Soft Prompting Tokens in LLMs Fail to Encode Structure — Sapienza · 2026-10-27
- Mathathon 2.0 launches with Terence Tao's SAIR, $1.5M in compute for teams — _sathvikr · 2026-10-27
- The 'sweet lesson' is real: two kinds of ML problems need opposite strategies — mike64_t · 2026-10-27
- PixGR: Pixel-space generative decoding for fast feed-forward 3D reconstruction — kwangmoo_yi · 2026-10-27
- UniAction: unified action conditioning lets one world model handle mixed action types — ZeYanjie · 2026-10-27
- Infini-AI Lab open-sources Hermit, a framework for agent harness evolution and continual learning — BeidiChen · 2026-10-27